Published in Intern Emerg Med on November 25, 2012
Effect of red yeast rice combined with antioxidants on lipid pattern, hs-CRP level, and endothelial function in moderately hypercholesterolemic subjects. Ther Clin Risk Manag (2016) 0.80
Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial. Nutr J (2015) 0.79
ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J (2011) 5.11
Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation (2009) 3.39
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J (2011) 2.29
The PANDORA study: peripheral arterial disease in patients with non-high cardiovascular risk. Intern Emerg Med (2011) 2.12
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res (2010) 2.09
Hyperuricemia and cardiovascular disease risk. Expert Rev Cardiovasc Ther (2014) 2.07
Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res (2010) 1.54
Cardiovascular health in migrants: current status and issues for prevention. A collaborative multidisciplinary task force report. J Cardiovasc Med (Hagerstown) (2014) 1.50
Irbesartan and hydrochlorothiazide association in the treatment of hypertension. Curr Vasc Pharmacol (2009) 1.40
Acute administration of angiotensin converting enzyme inhibitors in thrombolysed myocardial infarction patients is associated with a decreased incidence of heart failure, but an increased re-infarction risk. Cardiovasc Drugs Ther (2005) 1.39
Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella Heart Study. Intern Emerg Med (2013) 1.39
Idiopathic sudden hearing loss: another kind of circulatory risk should not be neglected. Eur Arch Otorhinolaryngol (2013) 1.39
Could statins exert a protective effect on epistaxis of systemic origin? Med Hypotheses (2010) 1.38
Prospects for the development of novel anti-hyperlipidemic drugs. Curr Opin Investig Drugs (2006) 1.27
Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium (2006) 1.27
Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Prev Cardiol (2011) 1.25
Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther (2012) 1.18
Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels (2007) 1.05
Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension. J Hypertens (2012) 1.04
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism (2009) 1.04
Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). BMC Public Health (2010) 0.99
Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J Hypertens (2006) 0.97
Central hemodynamic modifications in diabetes mellitus. Atherosclerosis (2013) 0.96
Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. BMC Public Health (2011) 0.96
Psychosocial factors and metabolic parameters: is there any association in elderly people? The Massa Lombarda Project. Aging Ment Health (2010) 0.96
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res (2007) 0.95
Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens (2007) 0.95
Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J Hypertens (2014) 0.95
Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens (2010) 0.93
Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res (2013) 0.93
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract (2012) 0.92
Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study. Fertil Steril (2008) 0.91
Hypertension: management perspectives. Expert Opin Pharmacother (2012) 0.91
Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. Curr Vasc Pharmacol (2009) 0.90
The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther (2003) 0.90
A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag (2007) 0.90
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol (2012) 0.89
Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate. Arch Med Sci (2013) 0.89
Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept. Arch Gerontol Geriatr (2004) 0.89
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract (2004) 0.89
Prevalence of peripheral arterial disease in patients at non-high cardiovascular risk. Rationale and design of the PANDORA study. BMC Cardiovasc Disord (2010) 0.88
Inner ear symptoms: can we use them to approach cardiovascular diseases? Intern Emerg Med (2014) 0.88
Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium (2007) 0.88
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med (2009) 0.88
Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. Heart Vessels (2009) 0.88
Cardiometabolic Risks and Obesity in the Young. N Engl J Med (2016) 0.88
Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects. Arch Med Sci (2012) 0.87
Cerebrovascular disease in Italy and Europe: it is necessary to prevent a 'pandemia'. J Cardiovasc Risk (2002) 0.87
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin (2009) 0.87
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther (2012) 0.87
Pulse pressure amplification, pressure waveform calibration and clinical applications. Atherosclerosis (2012) 0.86
2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. High Blood Press Cardiovasc Prev (2013) 0.86
Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. J Am Soc Hypertens (2013) 0.86
Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials. Curr Opin Cardiol (2002) 0.85
A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther (2003) 0.85
Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials. Am J Hypertens (2013) 0.85
Zofenopril and incidence of cough: a review of published and unpublished data. Ther Clin Risk Manag (2011) 0.84
Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium (2007) 0.84
Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study. Clin Exp Hypertens (2010) 0.84
[Disease management for heart failure patients: role of wireless technologies for telemedicine. The ICAROS project]. G Ital Cardiol (Rome) (2007) 0.84
Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res (2006) 0.83
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol (2010) 0.83
Long-term effect of a dietary education program on postmenopausal cardiovascular risk and metabolic syndrome: the Brisighella Heart Study. J Womens Health (Larchmt) (2010) 0.83
Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. Endothelium (2007) 0.83
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocr J (2010) 0.83
Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. Microvasc Res (2010) 0.82
Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. Blood Press (2009) 0.82
Hypertension and diabetes incidence: confounding factors. Hypertens Res (2011) 0.82
Relationship between serum uric acid and electrocardiographic alterations in a large sample of general population: data from the Brisighella Heart Study. High Blood Press Cardiovasc Prev (2014) 0.82
Evidence of clinically relevant efficacy for dietary supplements and nutraceuticals. Curr Hypertens Rep (2013) 0.82
Retracted Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study. J Diabetes Complications (2011) 0.82
How to avoid the depression of the adherence to antihypertensive treatment? J Hypertens (2013) 0.81
Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. Microvasc Res (2010) 0.81
Serum uric acid and impaired cognitive function in a cohort of healthy young elderly: data from the Brisighella Study. Intern Emerg Med (2014) 0.81
Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. Intern Med (2007) 0.81
Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother (2012) 0.81
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. Eur J Pharm Sci (2013) 0.81
Effects of antihypertensive drugs on central blood pressure in humans: a preliminary observation. Am J Hypertens (2013) 0.81
Metabolic syndrome, adipokines and hormonal factors in pharmacologically untreated adult elderly subjects from the Brisighella Heart Study historical cohort. Obes Facts (2012) 0.80
Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. Clin Exp Hypertens (2012) 0.80
Retracted Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. Pharmacol Res (2013) 0.80